Lindbrook Capital, LLC Theravance Biopharma, Inc. Transaction History

Lindbrook Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$8.29 - $9.92 $439 - $525	53 New	53 $0
Q4 2023 Jan 31, 2024	BUY	$8.58 - $11.4 $2,402 - $3,192	280 New	280 $3,000
Q4 2022 Jan 24, 2023	BUY	$9.65 - $11.34 $955 - $1,122	99 Added 300.0%	132 $0
Q3 2022 Nov 10, 2022	BUY	$8.39 - $10.22 $58 - $71	7 Added 26.92%	33 $0
Q2 2022 Aug 01, 2022	SELL	$8.41 - $10.34 $4,768 - $5,862	-567 Reduced 95.62%	26 $0
Q1 2022 Apr 21, 2022	BUY	$8.33 - $12.96 $4,939 - $7,685	593 New	593 $6,000
Q3 2020 Nov 03, 2020	SELL	$14.79 - $22.49 $635 - $967	-43 Closed	0 $0
Q1 2020 Apr 22, 2020	BUY	$17.84 - $31.21 $767 - $1,342	43 New	43 $1,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.